Clinical Trials Browser

Stomach Neoplasms

Rectal Neoplasms

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Rectal Neoplasms

Somatostatinoma, Carcinoma, Neuroendocrine

Esophageal Neoplasms

Colorectal Neoplasms

Anal Canal Carcinoma, Anus Neoplasms

Stomach Neoplasms

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Nasopharyngeal Carcinoma, Recurrence

Nasopharyngeal Neoplasms

Rectal Neoplasms

Stomach Neoplasms

Pancreatic Adenocarcinoma

Breast Neoplasms

Breast Neoplasms

Rectal Neoplasms

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Stage I Gastric Cancer AJCC v8

Rectal Neoplasms

Esophageal Squamous Cell Carcinoma

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Adenocarcinoma, Rectal Neoplasms

Adenocarcinoma of the Oesophagus

Stomach Neoplasms

Pancreatic Neoplasms

Breast Neoplasm Malignant Female

Pancreatic Neoplasms

Breast Neoplasms

Nasopharyngeal Carcinoma

Adenoma, Islet Cell

Locally Advanced Rectal Cancer

Breast Neoplasms

Cholangiocarcinoma

Colorectal Neoplasms

Gallbladder Neoplasms, Klatskin Tumor

Pancreatic Neoplasms

Stomach Neoplasms

DMMR Colorectal Cancer

Stomach Neoplasms

Stomach Neoplasms

Triple Negative Breast Neoplasms

Clinical Trials

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

LyRICX

Toco-CoR

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

ALTER-HN005

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

MK-7119-001

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Colon Neoadjuvant FOLFOXIRI Study

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

JANUS

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

NOAHS-ARC

PLATFORM

PANDA

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

DPDMAX

MAIBE

ORCHID

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

SAFIR02_Breast

PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery

AXOAXI

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

BETTER2

CRITICS-II

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer